RecruitingNCT07151222

Role of Red Blood Cells in Cardiovascular Disease

The Red Blood Cell as a Mediator and Therapeutic Target in Cardiovascular Disease


Sponsor

Karolinska Institutet

Enrollment

500 participants

Start Date

Jan 1, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

The risk of myocardial infarction is dependent on cardiovascular risk factors including type 2 diabetes (T2D) but underlying mechanisms are poorly understood. We identified that red blood cells (RBCs) mediate beneficial cardiovascular regulatory effects under hypoxic/ischemic conditions via signaling by nitric oxide (NO) and soluble guanylate cyclase (sGC) in the RBCs. The RBCs become dysregulated in T2D which induces endothelial and cardiac injury. This project investigates the signaling of RBCs in cardiovascular disease and explores novel therapeutic strategies that target RBC function in myocardial infarction and T2D. Aims To determine the * mechanisms behind cardioprotective effect of RBCs in myocardial infarction * signaling behind cardiovascular injury induced by RBCs in T2D Work plan RBCs collected from patients with myocardial infarction, patients with T2D and healthy controls are investigated in bioassays including isolated hearts of ischemia/reperfusion, endothelial function and cell cultures. Molecular mechanisms behind the effects of RBCs are identified with focus on the NO-sGC pathway in the RBCs. This project unravels the RBC as a mediator of cardiovascular disease and has the potential to identify novel therapeutic strategies by targeting RBC signaling.


Eligibility

Min Age: 25 YearsMax Age: 80 Years

Inclusion Criteria1

  • Type 2 diabetes

Exclusion Criteria1

  • \-

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Karolinska Institutet

Stockholm, Swsden, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07151222


Related Trials